Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

TFAP2C (transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma))

Written2013-10Maria V Bogachek, Ronald J Weigel
Department of Surgery, Carver College of Medicine, University of Iowa, 5269 CBRB, 500 Newton Road, Iowa City, Iowa 52242, USA (MVB); Department of Surgery, Carver College of Medicine, University of Iowa, 200 Hawkins Drive Room 1509 JCP, Iowa City, Iowa 52242, USA (RJW)

(Note : for Links provided by Atlas : click)

Identity

Alias_namestranscription factor AP-2 gamma (activating enhancer-binding protein 2 gamma)
Alias_symbol (synonym)AP2-GAMMA
ERF1
TFAP2G
hAP-2g
Other alias
HGNC (Hugo) TFAP2C
LocusID (NCBI) 7022
Atlas_Id 42528
Location 20q13.31  [Link to chromosome band 20q13]
Location_base_pair Starts at 56629302 and ends at 56639282 bp from pter ( according to hg19-Feb_2009)  [Mapping TFAP2C.png]
Note TFAP2C is a member of the retinoic acid-inducible, developmentally regulated family of AP-2 factors. TFAP2C regulates cell growth and differentiation during ectodermal development (Qiao et al., 2012; Hoffman et al., 2007). It plays a critical role in establishing the luminal phenotype of normal mammary cells during their differentiation process. TFAP2C was shown to be involved in regulation of ESR1 and luminal - associated genes in breast cancer (Woodfield et al., 2010). TFAP2C maintains breast cancer luminal phenotype through the induction of luminal-associated genes and repression of genes characteristic of the basal subtype.

DNA/RNA

 
  TFAP2C human gene including promoter, 7 exons (blue rectangles) and 6 introns. Modified from Entrez Gene (Genomic DNA).
Description TFAP2C consists of 7 encoding exons. The open reading frame of the coding region is 1353 bp. TFAP2C cDNA was isolated in 1996 (Williamson et al., 1996) and predicted protein was conserved with TFAP2A DNA-binding and dimerization domains, and differs in the N-terminal activation domain. The promoter lacks canonical binding sites for basal transcription factors such as TATA and CCAAT boxes, but contains a cluster of CpG islands and may rely on an initiator element for transcription (Li et al., 2002). A potential trophoblast cell-specific regulatory element located approximately 6 kb upstream of the murine Tfap2c gene transcription start site (Li and Kellems, 2003).
Transcription 3 splice variants are described (Ensembl).
Pseudogene No pseudogenes are reported.

Protein

Note Active TFAP2C forms consist of homo - and heterodimers and play an important role in activation of retinoic acid-mediated differentiation including development of the eyes, face, body wall, limbs, neural tube (Hoffman et al., 2007; Li and Cornell, 2007). Placental defect and embryonic death were reported as results of TFAP2C total knockdown.
TFAP2C protein was purified in 1997 (McPherson et al., 1997) from ESR1 - positive cell line, was designed as ERF1. TFAP2C, 450-aa protein, has 48 kDa molecular mass. TFAP2C has 65% sequence homology to TFAP2A overall and 76% identity in C-terminal part.
The consensus site from the ChIP-seq data, SCCTSRGGS (S=G/C, r=A/G), is consistent with the optimal binding site, GCCTGAGGG, which was determined by in vitro PCR-assisted binding site selection (Woodfield et al., 2010).
Estrogen receptor-alpha (ESR1) and HER2/c-erbB2 genes are regulated by TFAP2C (Bosher et al., 1995; McPherson et al., 1997; Delacroix et al., 2005; Woodfield et al., 2007) along with genes associated with luminal phenotype of breast cancer (Woodfield et al., 2010). Activity of TFAP2C at specific target genes depends upon epigenetic chromatin structure. The combination of increasing chromatin accessibility and inducing TFAP2C provides a more robust activation of the ESR1 gene in ESR1-negative breast cancer cells (Woodfield et al., 2009). TFAP2C repressed CD44 expression in basal-derived breast cancer (Spanheimer et al., 2013a). TFAP2C regulates the expression of GPX1, which influences the redox state and sensitivity to oxidative stress induced by peroxides (Kulak et al., 2013).
Wwox tumor suppressor protein inhibits TFAP2C oncogenic activity by sequestering it in the cytoplasm (Aqeilan et al., 2004).
Reporter and chromatin immunoprecipitation assays demonstrated a direct, functional interaction by TFAP2C at the CDKN1A proximal promoter. TFAP2C silencing coincided with acquisition of an active chromatin conformation at the CDKN1A locus and increased gene expression (Gee et al., 2009).
TFAP2C SUMOylation modification was described in mammalian cells and SUMO site was mapped to conserved lysine 10 (Eloranta and Hurst, 2002).
Epithelial hyperplasia and impaired differentiation were reported in Tfap2c overexpressing transgenic mice (Jäger et al., 2003).
 
  Assignment of TFAP2C functional domains. AA: aminoacids, K10: SUMOylation site, AD: activation domain, Di/DBD: dimerization domain/DNA binding domain (adapted from Williams and Tjian, 1991).
Description A helixloop-helix motif in the DNA binding domain binds to GC-rich consensus site, SCCTSRGGS (S=G/C, R=A/G) (Woodfield et al., 2010), in the promoters of target genes and mediates TFAP2C specific transcriptional activity.
Expression TFAP2C is widely expressed within secondary outgrowths in the human mammary gland by 19 weeks gestation. In the adult mammary gland TFAP2C expression can be found in epithelial and myoepithelial compartments.
TFAP2C expression was reported in 16-40 weeks placenta, 5-10 weeks decidu and chorion (Li et al., 2002).
TFAP2C is expressed in gonocytes at weeks 12-37 of gestation, indicating a role of this transcription factor in fetal germ cell development. TFAP2C and c-KIT, a known target of AP-2 transcription factors, were coexpressed in gonocytes, making a direct regulation possible. With increasing differentiation of fetal testis, gradual downregulation of TFAP2C from the 12th to 37th week of gestation was observed. Furthermore, TFAP2C was expressed abundantly in 25/25 IGCNUs, 52/53 testicular seminomas, 10/10 metastatic seminomas, 9/9 extragonadal seminomas and 5/5 dysgerminomas (Pauls et al., 2005).
Normal tissues with TFAP2C expression: colon, lymph node, brain, heart, kidney, liver, lung, thyroid, adrenal gland, ovary, prostate, testis.
Localisation Nuclear.
Function It plays a role in the development of the eyes, face, body wall, limbs, and neural tube (Hoffman et al., 2007; Li and Cornell, 2007). Deletion of Tcfap2c during development resulted in a specific reduction of upper layer neurons in the occipital cortex (Pinto et al., 2009). Conditional ablation of Tcfap2c results in a delay in skin development and abnormal expression of p63, K14, K1, filaggrin, repetin and secreted Ly6/Plaur domain containing 1, key genes required for epidermal development and differentiation (Guttormsen et al., 2008).
Heterozygous Tfap2c-knockout mice were detected to have decreased body size while homozygous mice died at 7-9 days of embryonic development due to failure of proliferation of extraembryonic trophectodermal cells (Werling and Schorle, 2002). TFAP2C is also implicated in the regulation of the adenosine deaminase (ADA) gene, a gene involved in purine metabolism found expressed at the maternal-fetal interface (Werling and Schorle, 2002).
Homology Mouse, Tfap2c (Mus musculus: NP_033361.2) (NCBI).
Predicted homology: chicken (Gallus gallus: XM_417497.4), zebrafish (Danio rerio: NM_001008576.1) (NCBI).

Mutations

Germinal 2 patients with deletions of chromosome 20q13.2-q13.3 were reported to have feeding difficulties, microcephaly, facial dysmorphism with high forehead, broad nasal bridge, small chin and malformed ears, mild psychomotor retardation, and hypotonia (Geneviève et al., 2005).
Somatic 39 mutations were detected after analysis of 8164 samples (COSMIC: gene overview for TFAP2C) without direct links to certain diseases pathogenesis.
Deletion analyses of the promoter and chloramphenicol acetyl transferase reporter gene assays indicate that the sequence between -746 and -575 is important for its expression in mammary carcinoma cell lines (Li et al., 2002).
Combined mutation of the three putative Sp sites reduced promoter activity by 80% in trophoblast and nontrophoblast cells, demonstrating the functional importance of these sites in regulating TFAP2C gene expression (Li and Kellems, 2003).

Implicated in

Note
  
Entity Breast cancer
Note TFAP2C plays a critical role in maintaining the luminal subtype of breast cancer. TFAP2C directly binds to promoters and activates ESR1 along with luminal-associated genes (Woodfield et al., 2010). TFAP2C repressed CD44 expression in basal-derived breast cancer (Spanheimer et al., 2013a). Regulation of Ret by TFAP2C occurs independently of ESR1 expression in breast carcinoma (Spanheimer et al., 2013b). TFAP2C regulates the expression of GPX1, which influences the redox state and sensitivity to oxidative stress induced by peroxides (Kulak et al., 2013).
Prognosis Resistance to Tamoxifen treatment and reduction of survival rate had correlation with TFAP2C overexpression (Guler et al., 2007). ERBB2-negative/AP-2-positive expression patients had a better prognosis than patients with ERBB2-positive/AP-2-positive tumors (Gee et al., 2009).
In primary breast cancer specimens, high TFAP2C and low CD44 expression were associated with pCR after neoadjuvant chemotherapy and could be predictive of tumors that have improved response to neoadjuvant chemotherapy (Spanheimer et al., 2013a).
Elevated expression levels of TFAP2C in breast tumors were reported as predictors of poor prognosis (Zhao et al., 2003) and advancing clinical grade (Sotiriou et al., 2006).
  
  
Entity Seminomatous germ cell tumors
Note Immunohistochemistry marker to the detection of germ cell tumors (Pauls et al., 2005).
  
  
Entity Melanoma
Note AP-2γ expression is lower in thick melanomas, it is associated with unfavourable histo-pathological parameters (increased vascularity, vascular invasion and mitoses) (Osella-Abate et al., 2012).
  
  
Entity Pre-eclampsia
Note Elevated TFAP2C concentrations are associated with human placental defects such as pre-eclampsia and intrauterine growth restriction (Kuckenberg et al., 2012).
  

Breakpoints

 

Bibliography

Identification of target genes of transcription factor activator protein 2 gamma in breast cancer cells.
Ailan H, Xiangwen X, Daolong R, Lu G, Xiaofeng D, Xi Q, Xingwang H, Rushi L, Jian Z, Shuanglin X.
BMC Cancer. 2009 Aug 11;9:279. doi: 10.1186/1471-2407-9-279.
PMID 19671168
 
Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor.
Aqeilan RI, Palamarchuk A, Weigel RJ, Herrero JJ, Pekarsky Y, Croce CM.
Cancer Res. 2004 Nov 15;64(22):8256-61.
PMID 15548692
 
The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma.
Bosher JM, Williams T, Hurst HC.
Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):744-7.
PMID 7846046
 
Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells.
Delacroix L, Begon D, Chatel G, Jackers P, Winkler R.
DNA Cell Biol. 2005 Sep;24(9):582-94.
PMID 16153159
 
Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumolated in vivo.
Eloranta JJ, Hurst HC.
J Biol Chem. 2002 Aug 23;277(34):30798-804. Epub 2002 Jun 18.
PMID 12072434
 
Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival.
Gee JM, Eloranta JJ, Ibbitt JC, Robertson JF, Ellis IO, Williams T, Nicholson RI, Hurst HC.
J Pathol. 2009 Jan;217(1):32-41. doi: 10.1002/path.2430.
PMID 18825690
 
Paternal deletion of the GNAS imprinted locus (including Gnasxl) in two girls presenting with severe pre- and post-natal growth retardation and intractable feeding difficulties.
Genevieve D, Sanlaville D, Faivre L, Kottler ML, Jambou M, Gosset P, Boustani-Samara D, Pinto G, Ozilou C, Abeguile G, Munnich A, Romana S, Raoul O, Cormier-Daire V, Vekemans M.
Eur J Hum Genet. 2005 Sep;13(9):1033-9.
PMID 15915160
 
Wwox and Ap2gamma expression levels predict tamoxifen response.
Guler G, Iliopoulos D, Guler N, Himmetoglu C, Hayran M, Huebner K.
Clin Cancer Res. 2007 Oct 15;13(20):6115-21.
PMID 17947476
 
Disruption of epidermal specific gene expression and delayed skin development in AP-2 gamma mutant mice.
Guttormsen J, Koster MI, Stevens JR, Roop DR, Williams T, Winger QA.
Dev Biol. 2008 May 1;317(1):187-95. doi: 10.1016/j.ydbio.2008.02.017. Epub 2008 Feb 21.
PMID 18353300
 
Tfap2 transcription factors in zebrafish neural crest development and ectodermal evolution.
Hoffman TL, Javier AL, Campeau SA, Knight RD, Schilling TF.
J Exp Zool B Mol Dev Evol. 2007 Sep 15;308(5):679-91.
PMID 17724731
 
Transcription factor AP-2gamma stimulates proliferation and apoptosis and impairs differentiation in a transgenic model.
Jager R, Werling U, Rimpf S, Jacob A, Schorle H.
Mol Cancer Res. 2003 Oct;1(12):921-9.
PMID 14573793
 
The role of transcription factor Tcfap2c/TFAP2C in trophectoderm development.
Kuckenberg P, Kubaczka C, Schorle H.
Reprod Biomed Online. 2012 Jul;25(1):12-20. doi: 10.1016/j.rbmo.2012.02.015. Epub 2012 Mar 3. (REVIEW)
PMID 22560121
 
Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer.
Kulak MV, Cyr AR, Woodfield GW, Bogachek M, Spanheimer PM, Li T, Price DH, Domann FE, Weigel RJ.
Oncogene. 2013 Aug 22;32(34):4043-51. doi: 10.1038/onc.2012.400. Epub 2012 Sep 10.
PMID 22964634
 
Sp1 and Sp3 Are important regulators of AP-2gamma gene transcription.
Li M, Kellems RE.
Biol Reprod. 2003 Oct;69(4):1220-30. Epub 2003 Jun 11.
PMID 12801994
 
The human transcription factor activation protein-2 gamma (AP-2gamma): gene structure, promoter, and expression in mammary carcinoma cell lines.
Li M, Wang Y, Yu Y, Nishizawa M, Nakajima T, Ito S, Kannan P.
Gene. 2002 Nov 13;301(1-2):43-51.
PMID 12490322
 
Redundant activities of Tfap2a and Tfap2c are required for neural crest induction and development of other non-neural ectoderm derivatives in zebrafish embryos.
Li W, Cornell RA.
Dev Biol. 2007 Apr 1;304(1):338-54. Epub 2006 Dec 23.
PMID 17258188
 
Identification of ERF-1 as a member of the AP2 transcription factor family.
McPherson LA, Baichwal VR, Weigel RJ.
Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4342-7.
PMID 9113991
 
Expression of AP-2alpha, AP-2gamma and ESDN in primary melanomas: correlation with histopathological features and potential prognostic value.
Osella-Abate S, Novelli M, Quaglino P, Orso F, Ubezio B, Tomasini C, Berardengo E, Bernengo MG, Taverna D.
J Dermatol Sci. 2012 Dec;68(3):202-4. doi: 10.1016/j.jdermsci.2012.09.008. Epub 2012 Sep 18.
PMID 23036739
 
Transcription factor AP-2gamma, a novel marker of gonocytes and seminomatous germ cell tumors.
Pauls K, Jager R, Weber S, Wardelmann E, Koch A, Buttner R, Schorle H.
Int J Cancer. 2005 Jun 20;115(3):470-7.
PMID 15700319
 
AP2gamma regulates basal progenitor fate in a region- and layer-specific manner in the developing cortex.
Pinto L, Drechsel D, Schmid MT, Ninkovic J, Irmler M, Brill MS, Restani L, Gianfranceschi L, Cerri C, Weber SN, Tarabykin V, Baer K, Guillemot F, Beckers J, Zecevic N, Dehay C, Caleo M, Schorle H, Gotz M.
Nat Neurosci. 2009 Oct;12(10):1229-37. doi: 10.1038/nn.2399. Epub 2009 Sep 13.
PMID 19749747
 
AP2gamma regulates neural and epidermal development downstream of the BMP pathway at early stages of ectodermal patterning.
Qiao Y, Zhu Y, Sheng N, Chen J, Tao R, Zhu Q, Zhang T, Qian C, Jing N.
Cell Res. 2012 Nov;22(11):1546-61. doi: 10.1038/cr.2012.122. Epub 2012 Sep 4.
PMID 22945355
 
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M.
J Natl Cancer Inst. 2006 Feb 15;98(4):262-72.
PMID 16478745
 
Expression of the RET proto-oncogene is regulated by TFAP2C in breast cancer independent of the estrogen receptor.
Spanheimer PM, Woodfield GW, Cyr AR, Kulak MV, White-Baer LS, Bair TB, Weigel RJ.
Ann Surg Oncol. 2013b Jul;20(7):2204-12. doi: 10.1245/s10434-012-2570-5. Epub 2012 Aug 10.
PMID 22878616
 
Transcription factor gene AP-2 gamma essential for early murine development.
Werling U, Schorle H.
Mol Cell Biol. 2002 May;22(9):3149-56.
PMID 11940672
 
AP-2gamma promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene.
Williams CM, Scibetta AG, Friedrich JK, Canosa M, Berlato C, Moss CH, Hurst HC.
EMBO J. 2009 Nov 18;28(22):3591-601. doi: 10.1038/emboj.2009.290. Epub 2009 Oct 1.
PMID 19798054
 
Analysis of the DNA-binding and activation properties of the human transcription factor AP-2.
Williams T, Tjian R.
Genes Dev. 1991b Apr;5(4):670-82.
PMID 2010091
 
Chromosomal mapping of the human and mouse homologues of two new members of the AP-2 family of transcription factors.
Williamson JA, Bosher JM, Skinner A, Sheer D, Williams T, Hurst HC.
Genomics. 1996 Jul 1;35(1):262-4.
PMID 8661133
 
Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells.
Woodfield GW, Chen Y, Bair TB, Domann FE, Weigel RJ.
Genes Chromosomes Cancer. 2010 Oct;49(10):948-62. doi: 10.1002/gcc.20807.
PMID 20629094
 
Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis.
Zhao C, Yasui K, Lee CJ, Kurioka H, Hosokawa Y, Oka T, Inazawa J.
Cancer. 2003 Jul 1;98(1):18-23.
PMID 12833450
 

Citation

This paper should be referenced as such :
Bogachek, MV ; Weigel, RJ
TFAP2C (transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma))
Atlas Genet Cytogenet Oncol Haematol. 2014;18(5):346-350.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/TFAP2CID42528ch20q13.html


External links

Nomenclature
HGNC (Hugo)TFAP2C   11744
Cards
AtlasTFAP2CID42528ch20q13
Entrez_Gene (NCBI)TFAP2C  7022  transcription factor AP-2 gamma
AliasesAP2-GAMMA; ERF1; TFAP2G; hAP-2g
GeneCards (Weizmann)TFAP2C
Ensembl hg19 (Hinxton)ENSG00000087510 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000087510 [Gene_View]  chr20:56629302-56639282 [Contig_View]  TFAP2C [Vega]
ICGC DataPortalENSG00000087510
TCGA cBioPortalTFAP2C
AceView (NCBI)TFAP2C
Genatlas (Paris)TFAP2C
WikiGenes7022
SOURCE (Princeton)TFAP2C
Genetics Home Reference (NIH)TFAP2C
Genomic and cartography
GoldenPath hg38 (UCSC)TFAP2C  -     chr20:56629302-56639282 +  20q13.31   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)TFAP2C  -     20q13.31   [Description]    (hg19-Feb_2009)
EnsemblTFAP2C - 20q13.31 [CytoView hg19]  TFAP2C - 20q13.31 [CytoView hg38]
Mapping of homologs : NCBITFAP2C [Mapview hg19]  TFAP2C [Mapview hg38]
OMIM601602   
Gene and transcription
Genbank (Entrez)AK301572 AK314272 BC035664 BC051829 U85658
RefSeq transcript (Entrez)NM_003222
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)TFAP2C
Cluster EST : UnigeneHs.473152 [ NCBI ]
CGAP (NCI)Hs.473152
Alternative Splicing GalleryENSG00000087510
Gene ExpressionTFAP2C [ NCBI-GEO ]   TFAP2C [ EBI - ARRAY_EXPRESS ]   TFAP2C [ SEEK ]   TFAP2C [ MEM ]
Gene Expression Viewer (FireBrowse)TFAP2C [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)7022
GTEX Portal (Tissue expression)TFAP2C
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ92754   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtQ92754  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProQ92754
Splice isoforms : SwissVarQ92754
PhosPhoSitePlusQ92754
Domains : Interpro (EBI)TF_AP2    TF_AP2_C    TF_AP2_gamma   
Domain families : Pfam (Sanger)TF_AP-2 (PF03299)   
Domain families : Pfam (NCBI)pfam03299   
Conserved Domain (NCBI)TFAP2C
DMDM Disease mutations7022
Blocks (Seattle)TFAP2C
SuperfamilyQ92754
Human Protein AtlasENSG00000087510
Peptide AtlasQ92754
HPRD03361
IPIIPI00023260   IPI01011996   IPI00791453   
Protein Interaction databases
DIP (DOE-UCLA)Q92754
IntAct (EBI)Q92754
FunCoupENSG00000087510
BioGRIDTFAP2C
STRING (EMBL)TFAP2C
ZODIACTFAP2C
Ontologies - Pathways
QuickGOQ92754
Ontology : AmiGOnegative regulation of transcription from RNA polymerase II promoter  RNA polymerase II regulatory region sequence-specific DNA binding  core promoter binding  transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding  transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding  DNA binding  transcription factor activity, sequence-specific DNA binding  protein binding  nucleus  nucleoplasm  nucleoplasm  mitochondrion  cytosol  regulation of transcription from RNA polymerase II promoter  transcription from RNA polymerase II promoter  cell-cell signaling  male gonad development  regulation of gene expression, epigenetic  regulation of cell proliferation  positive regulation of transcription from RNA polymerase II promoter  positive regulation of transcription from RNA polymerase II promoter  protein dimerization activity  
Ontology : EGO-EBInegative regulation of transcription from RNA polymerase II promoter  RNA polymerase II regulatory region sequence-specific DNA binding  core promoter binding  transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding  transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding  DNA binding  transcription factor activity, sequence-specific DNA binding  protein binding  nucleus  nucleoplasm  nucleoplasm  mitochondrion  cytosol  regulation of transcription from RNA polymerase II promoter  transcription from RNA polymerase II promoter  cell-cell signaling  male gonad development  regulation of gene expression, epigenetic  regulation of cell proliferation  positive regulation of transcription from RNA polymerase II promoter  positive regulation of transcription from RNA polymerase II promoter  protein dimerization activity  
REACTOMEQ92754 [protein]
REACTOME PathwaysR-HSA-8866911 [pathway]   
NDEx NetworkTFAP2C
Atlas of Cancer Signalling NetworkTFAP2C
Wikipedia pathwaysTFAP2C
Orthology - Evolution
OrthoDB7022
GeneTree (enSembl)ENSG00000087510
Phylogenetic Trees/Animal Genes : TreeFamTFAP2C
HOVERGENQ92754
HOGENOMQ92754
Homologs : HomoloGeneTFAP2C
Homology/Alignments : Family Browser (UCSC)TFAP2C
Gene fusions - Rearrangements
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerTFAP2C [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)TFAP2C
dbVarTFAP2C
ClinVarTFAP2C
1000_GenomesTFAP2C 
Exome Variant ServerTFAP2C
ExAC (Exome Aggregation Consortium)TFAP2C (select the gene name)
Genetic variants : HAPMAP7022
Genomic Variants (DGV)TFAP2C [DGVbeta]
DECIPHERTFAP2C [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisTFAP2C 
Mutations
ICGC Data PortalTFAP2C 
TCGA Data PortalTFAP2C 
Broad Tumor PortalTFAP2C
OASIS PortalTFAP2C [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICTFAP2C  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDTFAP2C
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch TFAP2C
DgiDB (Drug Gene Interaction Database)TFAP2C
DoCM (Curated mutations)TFAP2C (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)TFAP2C (select a term)
intoGenTFAP2C
NCG5 (London)TFAP2C
Cancer3DTFAP2C(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM601602   
Orphanet
MedgenTFAP2C
Genetic Testing Registry TFAP2C
NextProtQ92754 [Medical]
TSGene7022
GENETestsTFAP2C
Target ValidationTFAP2C
Huge Navigator TFAP2C [HugePedia]
snp3D : Map Gene to Disease7022
BioCentury BCIQTFAP2C
ClinGenTFAP2C
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD7022
Chemical/Pharm GKB GenePA36461
Clinical trialTFAP2C
Miscellaneous
canSAR (ICR)TFAP2C (select the gene name)
Probes
Litterature
PubMed63 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineTFAP2C
EVEXTFAP2C
GoPubMedTFAP2C
iHOPTFAP2C
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Mon May 22 09:24:56 CEST 2017

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.